Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH. Furst DE, et al. Among authors: van de putte lb. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1. Ann Rheum Dis. 2000. PMID: 11053077 Free PMC article. Review. No abstract available.
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH. Furst DE, et al. Among authors: van de putte lb. Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2. Ann Rheum Dis. 2003. PMID: 14532138 Free PMC article. Review. No abstract available.
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. van de Putte LB, et al. Among authors: van riel pl. Ann Rheum Dis. 2003 Dec;62(12):1168-77. doi: 10.1136/ard.2003.009563. Ann Rheum Dis. 2003. PMID: 14644854 Free PMC article. Clinical Trial.
Access to disease modifying treatments for rheumatoid arthritis patients.
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M. Furst DE, et al. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I129-30. doi: 10.1136/ard.58.2008.i129. Ann Rheum Dis. 1999. PMID: 10577989 Free PMC article. Review. No abstract available.
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.
Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van De Putte LB, van Riel PL, Rodriguez-Valverde V. Smolen JS, et al. Among authors: van de putte lb, van riel pl. Ann Rheum Dis. 2000 Jul;59(7):504-5. doi: 10.1136/ard.59.7.504. Ann Rheum Dis. 2000. PMID: 10873957 Free PMC article. Review. No abstract available.
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I; European Leflunomide Study Group. Scott DL, et al. Among authors: van de putte lb. Ann Rheum Dis. 2001 Oct;60(10):913-23. doi: 10.1136/ard.60.10.913. Ann Rheum Dis. 2001. PMID: 11557646 Free PMC article. Clinical Trial.
[Immunotherapy in rheumatoid arthritis; current status].
Breedveld FC, van de Putte LB. Breedveld FC, et al. Among authors: van de putte lb. Ned Tijdschr Geneeskd. 1996 Jun 15;140(24):1255-9. Ned Tijdschr Geneeskd. 1996. PMID: 8700279 Review. Dutch. No abstract available.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. van de Putte LB, et al. Among authors: van riel pl. Ann Rheum Dis. 2004 May;63(5):508-16. doi: 10.1136/ard.2003.013052. Ann Rheum Dis. 2004. PMID: 15082480 Free PMC article. Clinical Trial.
442 results